ASH: Daratumumab Aids Newly Diagnosed Multiple Myeloma

This article originally appeared here.
Share this content:
ASH: Daratumumab Aids Newly Diagnosed Multiple Myeloma
ASH: Daratumumab Aids Newly Diagnosed Multiple Myeloma

TUESDAY, Dec. 12, 2017 (HealthDay News) -- Bortezomib, melphalan, and prednisone, combined with daratumumab is associated with a lower risk of disease progression or death for patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, according to a study published online Dec. 12 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.

Maria-Victoria Mateos, M.D., Ph.D., from the University Hospital of Salamanca in Spain, and colleagues randomized 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone or with daratumumab until disease progression.

The researchers found that the 18-month progression-free survival rate was 71.6 percent and 50.2 percent in the daratumumab and control groups, respectively, at a median follow-up of 16.5 months (hazard ratio for disease progression or death, 0.50). The overall response rate was 90.9 and 73.9 percent, respectively, and rate of complete response or better was 42.6 and 24.4 percent, respectively. In the daratumumab and control groups, 22.3 and 6.2 percent, respectively, had results below the threshold for minimal residual disease.

"Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than a regimen without daratumumab," the authors write.

The study was funded by Janssen Research and Development, the manufacturer of daratumumab.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »